A new probabilistic rule for drug-dug interaction prediction

Jihao Zhou, Zhaohui Qin, Sara K. Quinney, Seongho Kim, Zhiping Wang, Menggang Yu, Jenny Y. Chien, Aroonrut Lucksiri, Stephen D. Hall, Lang Li

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

An innovative probabilistic rule is proposed to predict the clinical significance or clinical insignificance of DDI. This rule is coupled with a hierarchical Bayesian model approach to summarize substrate/inhibitor's PK models from multiple published resources. This approach incorporates between-subject and between-study variances into DDI prediction. Hence, it can predict both population-average and subject-specific AUCR. The clinically significant DDI, weak DDI, and clinically insignificant inhibitions are decided by the probabilities of predicted AUCR falling into three intervals, (-∞, 1.25), (1.25, 2), and (2, ∞). The main advantage of this probabilistic rule to predict clinical significance of DDI over the deterministic rule is that the probabilistic rule considers the sample variability, and the decision is independent of sampling variation; while deterministic rule based decision will vary from sample to sample. The probabilistic rule proposed in this paper is best suited for the situation when in vivo PK studies and models are available for both the inhibitor and substrate. An early decision on clinically significant or clinically insignificant inhibition can avoid additional DDI studies. Ketoconazole and midazolam are used as an interaction pair to illustrate our idea. AUCR predictions incorporating between-subject variability always have greater variances than population-average AUCR predictions. A clinically insignificant AUCR at population-average level is not necessarily true when considering between-subject variability. Additional simulation studies suggest that predicted AUCRs highly depend on the interaction constant K i and dose combinations.

Original languageEnglish (US)
Pages (from-to)1-18
Number of pages18
JournalJournal of Pharmacokinetics and Pharmacodynamics
Volume36
Issue number1
DOIs
StatePublished - Feb 1 2009

Fingerprint

Drug Interactions
Population
Ketoconazole
Bayes Theorem
Midazolam

Keywords

  • Area under the concentration curve ratio (AUCR)
  • Bayesian model
  • Drug-drug interaction (DDI)
  • Pharmacokinetics
  • Prediction

ASJC Scopus subject areas

  • Pharmacology

Cite this

A new probabilistic rule for drug-dug interaction prediction. / Zhou, Jihao; Qin, Zhaohui; Quinney, Sara K.; Kim, Seongho; Wang, Zhiping; Yu, Menggang; Chien, Jenny Y.; Lucksiri, Aroonrut; Hall, Stephen D.; Li, Lang.

In: Journal of Pharmacokinetics and Pharmacodynamics, Vol. 36, No. 1, 01.02.2009, p. 1-18.

Research output: Contribution to journalArticle

Zhou, J, Qin, Z, Quinney, SK, Kim, S, Wang, Z, Yu, M, Chien, JY, Lucksiri, A, Hall, SD & Li, L 2009, 'A new probabilistic rule for drug-dug interaction prediction', Journal of Pharmacokinetics and Pharmacodynamics, vol. 36, no. 1, pp. 1-18. https://doi.org/10.1007/s10928-008-9107-3
Zhou, Jihao ; Qin, Zhaohui ; Quinney, Sara K. ; Kim, Seongho ; Wang, Zhiping ; Yu, Menggang ; Chien, Jenny Y. ; Lucksiri, Aroonrut ; Hall, Stephen D. ; Li, Lang. / A new probabilistic rule for drug-dug interaction prediction. In: Journal of Pharmacokinetics and Pharmacodynamics. 2009 ; Vol. 36, No. 1. pp. 1-18.
@article{e5bd020eac614a4b8c267a4e39f6db87,
title = "A new probabilistic rule for drug-dug interaction prediction",
abstract = "An innovative probabilistic rule is proposed to predict the clinical significance or clinical insignificance of DDI. This rule is coupled with a hierarchical Bayesian model approach to summarize substrate/inhibitor's PK models from multiple published resources. This approach incorporates between-subject and between-study variances into DDI prediction. Hence, it can predict both population-average and subject-specific AUCR. The clinically significant DDI, weak DDI, and clinically insignificant inhibitions are decided by the probabilities of predicted AUCR falling into three intervals, (-∞, 1.25), (1.25, 2), and (2, ∞). The main advantage of this probabilistic rule to predict clinical significance of DDI over the deterministic rule is that the probabilistic rule considers the sample variability, and the decision is independent of sampling variation; while deterministic rule based decision will vary from sample to sample. The probabilistic rule proposed in this paper is best suited for the situation when in vivo PK studies and models are available for both the inhibitor and substrate. An early decision on clinically significant or clinically insignificant inhibition can avoid additional DDI studies. Ketoconazole and midazolam are used as an interaction pair to illustrate our idea. AUCR predictions incorporating between-subject variability always have greater variances than population-average AUCR predictions. A clinically insignificant AUCR at population-average level is not necessarily true when considering between-subject variability. Additional simulation studies suggest that predicted AUCRs highly depend on the interaction constant K i and dose combinations.",
keywords = "Area under the concentration curve ratio (AUCR), Bayesian model, Drug-drug interaction (DDI), Pharmacokinetics, Prediction",
author = "Jihao Zhou and Zhaohui Qin and Quinney, {Sara K.} and Seongho Kim and Zhiping Wang and Menggang Yu and Chien, {Jenny Y.} and Aroonrut Lucksiri and Hall, {Stephen D.} and Lang Li",
year = "2009",
month = "2",
day = "1",
doi = "10.1007/s10928-008-9107-3",
language = "English (US)",
volume = "36",
pages = "1--18",
journal = "Journal of Pharmacokinetics and Pharmacodynamics",
issn = "1567-567X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - A new probabilistic rule for drug-dug interaction prediction

AU - Zhou, Jihao

AU - Qin, Zhaohui

AU - Quinney, Sara K.

AU - Kim, Seongho

AU - Wang, Zhiping

AU - Yu, Menggang

AU - Chien, Jenny Y.

AU - Lucksiri, Aroonrut

AU - Hall, Stephen D.

AU - Li, Lang

PY - 2009/2/1

Y1 - 2009/2/1

N2 - An innovative probabilistic rule is proposed to predict the clinical significance or clinical insignificance of DDI. This rule is coupled with a hierarchical Bayesian model approach to summarize substrate/inhibitor's PK models from multiple published resources. This approach incorporates between-subject and between-study variances into DDI prediction. Hence, it can predict both population-average and subject-specific AUCR. The clinically significant DDI, weak DDI, and clinically insignificant inhibitions are decided by the probabilities of predicted AUCR falling into three intervals, (-∞, 1.25), (1.25, 2), and (2, ∞). The main advantage of this probabilistic rule to predict clinical significance of DDI over the deterministic rule is that the probabilistic rule considers the sample variability, and the decision is independent of sampling variation; while deterministic rule based decision will vary from sample to sample. The probabilistic rule proposed in this paper is best suited for the situation when in vivo PK studies and models are available for both the inhibitor and substrate. An early decision on clinically significant or clinically insignificant inhibition can avoid additional DDI studies. Ketoconazole and midazolam are used as an interaction pair to illustrate our idea. AUCR predictions incorporating between-subject variability always have greater variances than population-average AUCR predictions. A clinically insignificant AUCR at population-average level is not necessarily true when considering between-subject variability. Additional simulation studies suggest that predicted AUCRs highly depend on the interaction constant K i and dose combinations.

AB - An innovative probabilistic rule is proposed to predict the clinical significance or clinical insignificance of DDI. This rule is coupled with a hierarchical Bayesian model approach to summarize substrate/inhibitor's PK models from multiple published resources. This approach incorporates between-subject and between-study variances into DDI prediction. Hence, it can predict both population-average and subject-specific AUCR. The clinically significant DDI, weak DDI, and clinically insignificant inhibitions are decided by the probabilities of predicted AUCR falling into three intervals, (-∞, 1.25), (1.25, 2), and (2, ∞). The main advantage of this probabilistic rule to predict clinical significance of DDI over the deterministic rule is that the probabilistic rule considers the sample variability, and the decision is independent of sampling variation; while deterministic rule based decision will vary from sample to sample. The probabilistic rule proposed in this paper is best suited for the situation when in vivo PK studies and models are available for both the inhibitor and substrate. An early decision on clinically significant or clinically insignificant inhibition can avoid additional DDI studies. Ketoconazole and midazolam are used as an interaction pair to illustrate our idea. AUCR predictions incorporating between-subject variability always have greater variances than population-average AUCR predictions. A clinically insignificant AUCR at population-average level is not necessarily true when considering between-subject variability. Additional simulation studies suggest that predicted AUCRs highly depend on the interaction constant K i and dose combinations.

KW - Area under the concentration curve ratio (AUCR)

KW - Bayesian model

KW - Drug-drug interaction (DDI)

KW - Pharmacokinetics

KW - Prediction

UR - http://www.scopus.com/inward/record.url?scp=58249137368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249137368&partnerID=8YFLogxK

U2 - 10.1007/s10928-008-9107-3

DO - 10.1007/s10928-008-9107-3

M3 - Article

C2 - 19156505

AN - SCOPUS:58249137368

VL - 36

SP - 1

EP - 18

JO - Journal of Pharmacokinetics and Pharmacodynamics

JF - Journal of Pharmacokinetics and Pharmacodynamics

SN - 1567-567X

IS - 1

ER -